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The RNA binding protein Lin28 and its paralog Lin28B are associated with advanced human malignancies, including breast, ovarian, lung and liver cancer as well as chronic myeloid leukemia and germ cell tumors. A wealth of evidence suggests that Lin28/Lin28B promotes malignancy through inactivating the let-7 family microRNAs. Let-7 is viewed as tumor supressor, because it posttranscriptionally supresses an array of onco-genes and cell cycle-promoting genes by binding to the complementary sites in their 3'UTRs. It is widely accepted that Lin28/Lin28B inhibits the biogenesis of let-7, thereby derepressing these targets. A new study demonstrates that, in addition to let-7 inhibition, a direct mechanism of Lin28 contributes to the development and progression of human cancer. Dr Yingqun Huang and colleagues report that the mRNA for the human epidermal growth factor receptor 2 (HER2), a HER-family receptor tyrosine kinase known to play a critical role in cell proliferation and survival and also a major therapeutic target in breast cancer, is among several targets of Lin28 regulation. They show that Lin28 stimulates HER2 expression at the posttranscriptional level, and that enforced Lin28 expression promotes cancer cell growth via multiple mechanisms. Interestingly, this study demonstrates for the first time and based on a large-sized breast cancer cohort, the impact of Lin28 expression on the clinical outcome in human cancer. High Lin28 expression is a strong predictor of poor prognosis independent of known risk factors, including HER2, estrogen receptor (ER) and progesterone receptor (PR) status, thus marking Lin28 as a potentially new and independent prognostic marker for breast cancer.
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miRNAs modulate plant resistance to stresses
============================================
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Nitrogen deficiency represents a serious threat to agriculture and the scientific community gives high priority to breeding programs for nutrient stress tolerance. Stress responses depend on the correct regulation of gene expression, and recently, several microRNAs (miRNAs) have been shown to play a vital role in modulating plant resistance to stresses. A Mini-Review by Dr Silvia Quaggiotti and co-workers discusses the potential role of a number of nitrate-responsive miRNAs in the maize adaptation to nitrate fluctuations. Presented data suggest that nitrate depletion regulates the expression of genes involved in the starvation adaptive response by affecting the spatio-temporal expression patterns of specific miRNAs. Understanding of the miRNA-guided stress regulatory networks could provide new tools for the genetic improvement of nitrogen use efficiency of crops. Single miRNAs could regulate at the same time the expression of more than one gene implicated in the physiological adaptation to the low nitrogen input, which makes them excellent candidate targets for the improvement of the tolerance to nutritional deficiencies.
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Naturally occurring endo-siRNAs silence LINE-1 retrotransposons
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Long interspersed nuclear element 1 (LINE-1) retrotransposons are mutagens that are capable of generating deleterious mutations by inserting themselves into genes and affecting gene function in the human genome. In normal cells, the activity of LINE-1 retrotransposon is mostly repressed, maintaining a stable genome structure. In contrast, cancer cells are characterized by aberrant expression of LINE-1 retrotransposons, which, in principle, have the potential to contribute to genomic instability. The mechanistic pathways that regulate LINE-1 expression remain unclear. Using deep-sequencing small RNA analysis, Dr Danny Rangasamy and co-workers identified a subset of differentially expressed endogenous small interfering RNAs (endo-siRNAs) that directly regulate LINE-1 expression. Detailed analyses suggest that these endo-siRNAs are significantly depleted in human breast cancer cells compared with normal breast cells. The identified endo-siRNAs were perfectly complementary in sequence to the LINE-1 bidirectional promoters. Overexpression of these endo-siRNAs in cancer cells markedly silences endogenous LINE-1 expression through increased DNA methylation of the LINE-1 5\'-UTR promoter. The finding that endo-siRNAs can silence LINE-1 activity through DNA methylation suggests that a functional link exists between the expression of endo-siRNAs and LINE-1 retrotransposons in human cells.
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Silencing of RRM1 helps overcome gemcitabine resistance
=======================================================
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Gemcitabine is a deoxycytidine analog used for the treatment of a wide range of solid tumors, but its efficacy is often reduced due to the development of resistance. Ribonucleotide reductase (RR) catalyzes the conversion of ribonucleoside 5\'-diphosphates into their corresponding 2\'-deoxyribonucleotides. This reaction is rate limiting in the production of 2\'-deoxyribonucleoside 5\'-triphosphates (dNTPs), which are essential for the de novo synthesis of DNA. Gemcitabine diphosphate (dFdCDP) binds to the large subunit M1 of RR (RRM1) and inhibits RR, thereby depleting the cellular dNTP pools. RRM1 has been identified as the key determinant of gemcitabine resistance, and tumor cells that overexpress RRM1 are resistant to the cytotoxicity of gemcitabine. A new study set out to test the hypothesis that downregulation of RRM1 expression would increase the susceptibility of resistant cancer cells to gemcitabine. Dr Zhengron Cui and colleagues used RRM1-specific small interfering RNA (siRNA), complexed with polyethylenimine, to effectively downregulate the expression of RRM1 protein in mouse tumor cells that overexpress RRM1, both in vitro and in vivo. They found that systemic administration of the RRM1-specific siRNA significantly inhibits the growth of RRM1-overexpressing tumors in mice and sensitizes the tumors to gemcitabine treatment. The study suggests that silencing RRM1 expression using siRNA could potentially be an effective strategy to overcome gemcitabine resistance.
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